Mazdutide

What it is

Mazdutide (LY3305677, IBI362) is a dual GLP-1/glucagon receptor agonist developed by Innovent Biologics under license from Eli Lilly. In 2025, China’s National Medical Products Administration approved mazdutide for chronic weight management and for type 2 diabetes. Mazdutide is not FDA-approved for any use in the United States.

Mechanism of action

Proposed mechanisms come from laboratory, animal, and clinical pharmacology research. Mazdutide is designed as a dual agonist at GLP-1 and glucagon receptors. GLP-1 receptor activation is associated with glucose-dependent insulin secretion, glucagon suppression, and reduced appetite; glucagon receptor activation has been proposed to affect energy expenditure, similar to what has been proposed for retatrutide. The dual mechanism (without GIP) distinguishes it from tirzepatide and retatrutide.

Clinical evidence

Phase II and III trials conducted mainly in China have been published; these findings have not been evaluated by the FDA, and benefit has not been established under US review.

Why we don’t prescribe it at The Tide

Mazdutide is not FDA-approved and not available through legal channels in the US. We do not prescribe medications without appropriate regulatory approval and supply chain.

Side effects and contraindications

Adverse events reported in clinical trials have been described as similar to those of other incretin-based therapies, mainly gastrointestinal. Long-term safety has not been established. Products sold outside regulated channels may vary in purity, dose, and sterility.